PRESS RELEASE published on 05/15/2024 at 07:30, 6 months 6 days ago Informations privilégiées / Communiqué sur comptes, résultats MaaT Pharma annonce le succès de son offre globale de 19,2 millions d'euros pour financer ses activités de R&D en biotechnologie clinique avancée, incluant des essais cliniques et le développement de son portefeuille thérapeutique Essais Cliniques Offre Globale MaaT Pharma Biotechnologie Clinique Portefeuille Thérapeutique
PRESS RELEASE published on 05/15/2024 at 07:30, 6 months 6 days ago Inside Information / News release on accounts, results MaaT Pharma announces successful completion of 19.2 million euros Global Offering with new shares, aims to fund R&D activities, Phase 3 trials, and broaden pipeline Biotechnology Fundraising Clinical Trials Global Offering MaaT Pharma
BRIEF published on 05/14/2024 at 19:39, 6 months 6 days ago MaaT Pharma Announces 18 Million Euro Global Offering and Strategic Developments Financial Strategy Phase 3 Trial Clinical-stage Biotechnology Global Offering Microbiome Ecosystem Therapies
BRIEF published on 05/14/2024 at 19:39, 6 months 6 days ago MaaT Pharma annonce une offre mondiale et des développements stratégiques de 18 millions d'euros Stratégie Financière Essai De Phase 3 Offre Globale Thérapies Écosystémiques Du Microbiome Biotechnologie Au Stade Clinique
PRESS RELEASE published on 05/14/2024 at 19:34, 6 months 6 days ago Inside Information / News release on accounts, results MaaT Pharma launches a global offering of approximately 18 million euros to fund R&D activities and expand shareholder base. Current shareholders commit to significant subscriptions Global Offering MaaT Pharma 18 Million Euros R&D Activities Shareholder Commitments
PRESS RELEASE published on 05/14/2024 at 19:34, 6 months 6 days ago Informations privilégiées / Communiqué sur comptes, résultats MaaT Pharma lance une augmentation de capital de 18 millions d'euros pour financer ses activités de R&D, incluant des essais cliniques aux États-Unis et en Europe Actionnaires Augmentation De Capital R&D Essais Cliniques MaaT Pharma
Published on 11/21/2024 at 12:00, 1 hour 4 minutes ago Alset AI Announces Full Repayment of $3.7 Million Secured Loan with Interest from Portfolio Company, Significantly Strengthening Balance Sheet
Published on 11/21/2024 at 12:00, 1 hour 4 minutes ago Battery X Metals Commences Strategic Initiatives to Strengthen Balance Sheet
Published on 11/21/2024 at 11:30, 1 hour 34 minutes ago FireFox Trenching Returns More High-Grade Gold at the Mustajärvi Gold Project in Lapland, Finland
Published on 11/21/2024 at 10:03, 3 hours 1 minute ago Pixotope Launches Revolutionary AI-Powered Graphics Integration Tool for Broadcast Industry
Published on 11/21/2024 at 10:00, 3 hours 4 minutes ago BluSky Carbon JV Entity BluMountain Enters into JV Partnership in Southeastern USA
Published on 11/21/2024 at 12:35, 29 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 49 minutes ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 11:30, 1 hour 34 minutes ago APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
Published on 11/21/2024 at 06:58, 6 hours 6 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 6 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 6 minutes ago Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 16 hours 57 minutes ago Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 44 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
